These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36223124)

  • 1. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma-Reply.
    Shoucair S; Yu J
    JAMA Surg; 2023 Jan; 158(1):103-104. PubMed ID: 36223124
    [No Abstract]   [Full Text] [Related]  

  • 2. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.
    Wang L; Niu W
    JAMA Surg; 2023 Jan; 158(1):102-103. PubMed ID: 36223123
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability".
    Krasinskas AM
    Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis.
    Wang H; Zhao Q
    Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
    Pai RK; Pai RK
    Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
    Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 9. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
    Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
    Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME
    AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875
    [No Abstract]   [Full Text] [Related]  

  • 13. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 14. Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives.
    Grützmann R; Saeger HD; Lüttges J; Schackert HK; Kalthoff H; Klöppel G; Pilarsky C
    Int J Colorectal Dis; 2004 Sep; 19(5):401-13. PubMed ID: 14745573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
    Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
    Nagaria TS; Wang H; Chatterjee D; Wang H
    Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic ductal carcinoma: from the bench to the bedside.
    Pezzilli R
    JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrosis following neoadjuvant treatment of PDAC: Less is not always more.
    Moten AS
    Am J Surg; 2024 Jun; 232():8. PubMed ID: 38092641
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of response in neoadjuvant therapy for exocrine pancreatic cancer.
    Vitello DJ; Bentrem DJ
    J Surg Oncol; 2021 May; 123(6):1449-1459. PubMed ID: 33831249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.